2. Search Result
Search Result
Results for "

METTL1

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Recombinant Proteins

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-178159
    SA91-0178

    		RNA MTase Inflammation/Immunology
    SA91-0178 is a METTL1 inhibitor. SA91-0178 inhibits m 7G methylation of RNA, reduces SARM1 stability, mitigates NAD + depletion and metabolic reprogramming in macrophages. SA91-0178 demonstrates excellent protective efficacy against multiple organ injury in cecal ligation and puncture (CLP)-induced and ischemia/reperfusion (I/R)-induced mice. SA91-0178 can be used for the study of systemic inflammatory diseases [1].
    SA91-0178
  • HY-162080
    METTL1-WDR4-IN-1
    1 Publications Verification

    		 DNA Methyltransferase Pyruvate Kinase Cancer
    METTL1-WDR4-IN-1 (Compound 1) is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC50 = 144 μM). METTL1-WDR4-IN-1 inhibits the m 7G methyltransferase activity of the METTL1-WDR4 complex, blocking m 7G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8 + T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy [1] .
    METTL1-WDR4-IN-1
  • HY-162082
    METTL1-WDR4-IN-2

    		DNA Methyltransferase Cancer
    METTL1-WDR4-IN-2, an adenosine derivative, is a selective methyltransferase Like 1 (METTL1)-WDR4 inhibitor with an IC50 of 41 μM. METTL1-WDR4-IN-2 shows selectivity against METTL3-14 (IC50 of 958 μM) and METTL16 (IC50 of 208 μM). METTL1-WDR4-IN-2 can be used for the study of cancer [1].
    METTL1-WDR4-IN-2
  • HY-RS08353
    METTL1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    METTL1 Human Pre-designed siRNA Set A contains three designed siRNAs for METTL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    METTL1 Human Pre-designed siRNA Set A
    METTL1 Human Pre-designed siRNA Set A
  • HY-RS17432
    Mettl1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mettl1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mettl1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mettl1 Mouse Pre-designed siRNA Set A
    Mettl1 Mouse Pre-designed siRNA Set A
  • HY-RS23887
    Mettl1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mettl1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mettl1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mettl1 Rat Pre-designed siRNA Set A
    Mettl1 Rat Pre-designed siRNA Set A
  • HY-162080A
    METTL1-WDR4-IN-1 TFA
    1 Publications Verification

    		 DNA Methyltransferase Pyruvate Kinase Cancer
    METTL1-WDR4-IN-1 (Compound 1) TFA is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC50=144 μM). METTL1-WDR4-IN-1 TFA inhibits the m 7G methyltransferase activity of the METTL1-WDR4 complex, blocking the m 7G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 TFA can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8 + T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 TFA can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy [1] .
    METTL1-WDR4-IN-1 TFA
  • HY-178947
    ZINC13000658

    		METTL3 Apoptosis Cancer
    ZINC13000658 is a METTL inhibitor. ZINC13000658 exhibits significant anti proliferative activity in various cells and can induce G1 phase cell cycle arrest and apoptosis such as HepG2 (IC50 = 5.632 µM) and SNU-449 (IC50 = 6.184 µM) cells. ZINC13000658 may be related to the inhibition of the activity of multiple methyltransferases such as METTL1, 3, 6, 16, 18, etc. ZINC13000658 can be used for research on various types of cancer [1].
    ZINC13000658

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: